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Background: Pulmonary hypertension (PH) is a comorbidity reported in patients with cystic ﬁbrosis (CF) with research limited to single-center
studies.
Methods: To assess the impact of PH in patients with CF who received a lung transplant (LTx), the United Network for Organ Sharing was queried
from 1987 to 2012, restricting analysis to transplant patients 6–55 years old between 1/1/2005 and 7/6/2011.
Results: Of 23,951 lung transplants, 1177 met inclusion criteria with 831 having mean pulmonary artery pressure (mPAP) data available. For the
entire cohort, mean age was 30.3 (SD = 9.2, range 12–55), and mean mPAP was 26.5 (SD = 7.8, range 5–66) mm Hg. A total of 470 (57%) had
PH deﬁned as mPAP ≥ 25 mm Hg. Comparing PH to non-PH groups, mean forced expiratory volume in one second (FEV1) was 24.4
(SD = 13.8) vs. 26 (SD = 13.9) % of predicted, mean supplemental oxygen requirement at rest was 4.5 (SD = 4.1) vs. 3.7 (SD = 3.0) liters per
minute, and mean lung allocation score was 49 (SD = 16) vs. 43 (SD = 12), respectively. For the PH group, median survival was 84.4 months
compared to 67.1 months for the non-PH group (log-rank p-value = 0.326). The adjusted hazard ratio for PH vs. non-PH was 0.862 (95% CI:
0.653–1.138; p = 0.293), thus indicating no statistically signiﬁcant effect of PH on survival.
Conclusions: A high prevalence of PH was found in CF patients prior to LTx. Based on our models despite PH being prevalent, there is no strong
evidence suggesting that it signiﬁcantly alters the risk of death in CF patients after LTx.
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Cystic fibrosis (CF) is an autosomal recessive, multisystem
disease characterized by recurrent respiratory infections and
chronic respiratory decline. With advancing lung disease,
alveolar hypoxia in patients with CF places them at increased
risk for the development of pulmonary hypertension (PH) [1].by Elsevier B.V. All rights reserved.
Table 1
Study population.
N
All lung transplants 23,951
First transplant, excluding those with
re-transplants or multiple transplants on the same day
23,023
Recipients with diagnosis of cystic fibrosis 3550
Recipients age 6–55 years of age 3506
Transplants occurring between 1/1/2005 and 7/6/2011 1323
Cadaveric transplants only 1318
One drug group only, no OKT3, Zenapax,
ANTIICAM1, ANTILFA1, DAB486IL2, NRATGNRATS,
OKT4, T10B9 or XOMAZYMECD5
1180
Survival status is present, patient and graft survival time is N0 1177
Patients have hemodynamics mPAP (mm Hg) a 834
mPAPa ≥5 mm Hg 831
a mPAP = mean pulmonary artery pressure.
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disease, the recognition of PH may provide prognostic value
and an opportunity for therapeutic intervention [2,3].
Although CF is associated with PH and cor pulmonale
[4–19], limited data exists regarding the prevalence of PH in
CF with the majority of these done using Doppler echocardi-
ography, which has limitations. More recent studies using right
heart catheterization (RHC) in CF has provided some insight
into the prevalence [4–6].
Using an available database with patients undergoing lung
transplantation (LTx) in the United States, we sought to evaluate
the prevalence of PH in a large cohort of patients with CF. Our
goal was to describe the relationship between PH, defined as
having mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg
on RHC [20,21], and overall survival after LTx in patients with
CF.
2. Methods
2.1. Database
We retrospectively evaluated data from lung transplant
recipients with CF who were registered in the Organ Procurement
and Transplant Network (OPTN) Standard Transplant Analysis
and Research (STAR) Database [22]. With the National Organ
Transplant Act of 1984, the OPTN was established by the
United States Congress. The United Network for Organ Sharing
(UNOS) is a private, nonprofit organization that administers
the OPTN under a federal contract. The STAR database is
administrated through UNOS/OPTN as overseen by the United
States Department of Health and Human Services. The UNOS/
OPTN STAR database maintains data elements reflecting donor
characteristics (e.g., donor mechanism of death, donor age, donor
gender), pre-transplant recipient characteristics (e.g., indication
for transplantation, recipient age, recipient gender, mPAP
obtained by RHC), and post-transplant recipient characteristics
and outcomes (e.g., length of stay, recipient survival, develop-
ment of postoperative complication) for solid organ transplants
from 1987 to present. The data are extracted by the individual
centers and submitted as aggregate data to the OPTN United
States Scientific Registry of Transplant Recipients (SRTR),
which collates and manages the data per the above referenced
contract.
2.2. Data analysis
This retrospective review was approved by The Ohio State
University Wexner Medical Center Institutional Review Board
with a waiver of the need for individual consent (IRB#
2012H0306). We queried the UNOS/OPTN thoracic database
for all lung transplants from January 1987 to November 2012.
For purposes of this analysis, we limited our analysis to
transplants from 1/1/2005 to 7/6/2011. Data prior to 2005 was
excluded in order to be able to use lung allocation score, which
was implemented by UNOS in May 2005. The last status
update in our dataset was 7/6/2012; therefore, the cutoff date of
7/6/2011 was selected to allow for the potential for at least ayear of follow-up time per patient. The mPAP data were
potentially available at both time of listing and transplant; when
present, values at transplant were used (n = 789). Note that of
the 680 patients with both listing and transplant values, 632
(93%) had identical entries for both listing and transplant.
Forty-five patients had a missing transplant value and the
listing value was used instead; 343 had missing values at both
listing and transplant. In addition, three patients had mPAP
values less than 5, which were considered unreasonable and set
to missing. Based on the 831 available mPAP values, patients
were then categorized as having PH (≥25 mm Hg) or not
(b25 mm Hg).
2.3. Statistical methods
Demographic variables of interest were summarized for the
PH and non-PH groups separately. Kaplan–Meier estimates of
the survival function were produced to assess crude differences in
overall survival, and the log-rank test was performed to test for
differences in the survival functions. Cox proportional hazards
models were used to calculate hazard ratios (HR) and 95%
confidence intervals (CI) for PH vs. non-PH for both a minimally
adjusted and multivariable model. The minimally adjusted model
included year of transplant with the baseline hazard stratified
by region. Due to evidence of non-proportional hazards, the
interaction between year of transplant and time (natural log scale)
was also included in the model. In addition to year of transplant
and region, the multivariable model included induction immu-
nosuppression (yes/no), age of recipient, end-match lung
allocation score, diabetes, recipient body mass index, recipient
gender, and steroid use. Recipient gender was included due to the
observed differences in the frequencies between the PH and
non-PH groups. All additional factors in the multivariable model
were chosen a priori based on their clinical relevance to survival.
The presence of significant two-way interactions with any of
the covariates and PH was assessed. Similarly, due to evidence
of non-proportional hazards, the interactions between year of
transplant, age of recipient, end-match lung allocation score, and
steroid use with time (natural log scale) were included in the
Table 2
Characteristics and demographics by mean mPAP (mean pulmonary artery pressure) mm Hg.
Variable Level Mean PAP (mean) mm Hg Total (n = 831)
5–24 (n = 361) 25–66 (n = 470)
PAP (mean) mm Hg mean (SD) 20.1 (3.4) 31.4 (6.5) 26.5 (7.8)
(min, max) (5,24) (25, 66) (5, 66)
Year of transplant 2005 34 (9%) 62 (13%) 96
2006 67 (19%) 53 (11%) 120
2007 43 (12%) 61 (13%) 104
2008 42 (12%) 64 (14%) 106
2009 61 (17%) 82 (17%) 143
2010 68 (19%) 91 (19%) 159
2011 46 (13%) 57 (12%) 103
Antibody based induction agent No 198 (55%) 247 (53%) 445
Yes 163 (45%) 223 (47%) 386
Ischemic time Missing 23 (6%) 39 (8%) 62
b4 h 36 (10%) 46 (10%) 82
4–6 h 172 (48%) 224 (48%) 396
N6 h 130 (36%) 161 (34%) 291
Recipient race Caucasian 351 (97%) 451 (96%) 802
African American 6 (2%) 6 (1%) 12
Other 4 (1%) 13 (3%) 17
Donor race Caucasian 224 (62%) 313 (67%) 537
African American 65 (18%) 77 (16%) 142
Other 72 (20%) 80 (17%) 152
Donor/recipient race match No match 143 (40%) 161 (34%) 304
Match 218 (60%) 309 (66%) 527
Recipient gender F 178 (49%) 201 (43%) 379
M 183 (51%) 269 (57%) 452
Donor gender F 160 (44%) 185 (39%) 345
M 201 (56%) 285 (61%) 486
Donor/recipient gender match No match 126 (35%) 156 (33%) 282
Match 235 (65%) 314 (67%) 549
HLA mismatch level Missing 41 (11%) 56 (12%) 97
HLA mismatch N 4 118 (33%) 163 (35%) 281
HLA mismatch ≤ 4 202 (56%) 251 (53%) 453
Serum creatinine at time of transplant Missing 2 (1%) 0 (0%) 2
Creatinine ≤ 2 357 (99%) 466 (99%) 823
Creatinine N 2 2 (1%) 4 (1%) 6
Steroids Missing 9 (2%) 22 (5%) 31
No 255 (71%) 317 (67%) 572
Yes 97 (27%) 131 (28%) 228
Diabetes Missing 1 (0%) 3 (1%) 4
No 209 (58%) 249 (53%) 458
Yes 151 (42%) 218 (46%) 369
Cytomegalovirus match Missing 19 (5%) 11 (2%) 30
No match 197 (55%) 283 (60%) 480
Match 145 (40%) 176 (37%) 321
Recipient age at time of transplant # Missing Missing = 0 Missing = 0 Missing = 0
mean (SD) 30.1 (9.3) 30.5 (9.2) 30.3 (9.2)
(min, max) (12, 55) (12, 55) (12, 55)
Calculated recipient body mass index # Missing Missing = 1 Missing = 0 Missing = 1
mean (SD) 19.5 (2.7) 19.4 (2.8) 19.5 (2.8)
(min, max) (13.2, 37.6) (11.5, 34) (11.5, 37.6)
Lung allocation score at match time # Missing Missing = 7 Missing = 12 Missing = 19
mean (SD) 42.9 (11.9) 48.8 (16) 46.2 (14.7)
(min, max) (32, 92.6) (29.8, 95.2) (29.8, 95.2)
Serum creatinine at time of transplant # Missing Missing = 2 Missing = 0 Missing = 2
mean (SD) 0.7 (0.3) 0.7 (0.3) 0.7 (0.3)
(min, max) (0.2, 3.9) (0.3, 2.6) (0.2, 3.9)
Total serum albumin at listing (pre-1/1/2007) # Missing Missing = 25 Missing = 32 Missing = 57
mean (SD) 3.5 (0.7) 3.5 (0.7) 3.5 (0.7)
(min, max) (0.5, 5.2) (0.5, 7.6) (0.5, 7.6)
Total bilirubin (mg/dL) # Missing Missing = 4 Missing = 7 Missing = 11
mean (SD) 0.5 (0.9) 0.5 (1.9) 0.5 (1.6)
(min, max) (0.1, 16) (0.1, 40) (0.1, 40)
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Table 2 (continued)
Variable Level Mean PAP (mean) mm Hg Total (n = 831)
5–24 (n = 361) 25–66 (n = 470)
O2 requirement at rest (L/min) # Missing Missing = 1 Missing = 3 Missing = 4
mean (SD) 3.7 (3) 4.5 (4.1) 4.1 (3.7)
(min, max) (0, 20) (0, 20) (0, 20)
Pulmonary status: FEV1% predicted at transplant # Missing Missing = 10 Missing = 15 Missing = 25
mean (SD) 26 (13.9) 24.4 (13.8) 25.1 (13.8)
(min, max) (5, 106) (9, 120) (5, 120)
Pulmonary status: FVC % predicted at transplant # Missing Missing = 7 Missing = 10 Missing = 17
mean (SD) 40.6 (13.2) 37.6 (13.4) 38.9 (13.4)
(min, max) (13, 92) (11, 130) (11, 130)
Cardiac output (L/min) at transplant # Missing Missing = 47 Missing = 56 Missing = 103
mean (SD) 5.1 (1.4) 5.6 (1.5) 5.4 (1.5)
(min, max) (1, 10.3) (2.3, 12.9) (1, 12.9)
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity.
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performed using Stata 12's mi commands in order to assess the
impact of the missing mPAP data. In two separate procedures,
325 mPAP values as well as 325 PH values were imputed using
regression methods (linear and logistic, respectively); 20 imputed
datasets were generated each. Variables used to impute the mPAP
data include age, gender, forced expiratory volume in one second
(FEV1), O2 requirement at rest, and recipient body mass index as
well as final status (alive or dead) and total follow-up time. Using
the two sets of 20 imputed datasets, changes to the Coxmodel HR
and CI from the complete case model results were assessed.
Analyses were performed using SAS/STAT software version 9.2
(SAS Institute Inc., Cary, NC) and Stata 12.1 (Stata Corporation,
College Station, TX).3. Results
3.1. Study population
Table 1 presents inclusion and exclusion criteria for our
study. Of the 23,951 lung transplants in the database, 1177 met
inclusion criteria with 831 having mPAP data available. A total
of 470/831 patients (57%) were listed as having PH. Table 2
summarizes the demographics between the PH and non-PH
groups, as well as overall.
For the entire cohort, the mean mPAP was 26.5 (SD = 7.8,
range 5–66) mm Hg whereas the mean mPAP was 31.4 (SD =
6.5, range 25–66) mm Hg and 20.1 (SD = 3.4, range 5–24)
mm Hg for the PH and non-PH groups, respectively. The
patients in the PH group had a lower FEV1% of predicted
(mean 24.4% vs. 26%, p = 0.004) and a higher concentration of
supplemental oxygen requirement at rest (mean 4.5 L/min vs.
3.7 L/min, p = 0.040). The mean lung allocation score was
higher for the PH group compared to non-PH group, 49 (SD =
16, range 30–95) vs. 43 (SD = 12, range 32–93), respectively
(p b 0.001). There was a higher proportion of male patients in
the PH group compared to the non-PH patients (57% vs. 51%,
respectively, p = 0.061). All other non-pulmonary function
demographic characteristics were similar between the PH andnon-PH groups (p N 0.05), including mean age (30.1 vs. 30.5,
respectively).
3.2. Overall survival
Of the 831 patients included in the analysis, there were a
total of 253 known deaths during the study period (mean
follow-up time = 32.3 months). Approximately 32% of the
patients in the non-PH group died during follow-up (117/361),
compared to 29% (136/470) in the PH group. The mean
follow-up time for the PH and non-PH groups was 30.9 months
and 31.2 months, respectively. There was no significant
difference observed in the Kaplan–Meier estimates of the
survival function for PH vs. non-PH (p = 0.326). The median
survival times for the PH and non-PH groups were 84.4 and
67.1 months, respectively (Fig. 1).
3.3. Cox proportional hazards modeling for PH vs. non-PH
The hazard ratio for PH vs. non-PH from the minimally
adjusted model was 0.830 (95% CI: 0.645–1.067; p = 0.146),
suggesting that the presence of PH may have a protective, albeit
not statistically significant, effect on survival (Table 3). Results
from the multivariable model were similar: the adjusted hazard
ratio for PH vs. non-PH was 0.862 (95% CI: 0.653–1.138; p =
0.293). As an additional check, a second multivariable model
was considered which contained all variables from the original
multivariable model in addition to the following measures of
pulmonary function: O2 requirement at rest, FEV1% of
predicted at transplant, forced vital capacity (FVC) % of
predicted at transplant, and cardiac output. The results of this
model were consistent to those from the minimally adjusted and
original multivariable model (HR = 0.787; 95% CI: 0.579–
1.071; p = 0.126).
Demographics were compared between the 831 patients
with mPAP values and the 346 patients missing mPAP values.
There were significant differences observed in several demo-
graphic variables between the respective groups. A greater
proportion of those with non-missing data were Caucasian
(97% vs. 89%, p b 0.001), female (56% vs. 46%, p = 0.001)
Number at Risk
Group
Time (Months)
0 12 24 36 48 60 72 84 96
Mean PAP < 25 361 273 187 131 87 56 19 4 0
Mean PAP ≥ 25 470 364 249 173 101 60 23 8 0
Fig. 1. Kaplan–Meier estimates of post-lung transplant survival in recipients with pulmonary arterial hypertension (25+) and recipients who do not (b25) (log-rank
p-value = 0.326). The number at risk over time is presented in the table below the x-axis.
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mismatch scores ≤ 4 vs. 41%, p = 0.002). Additionally, those
with non-missingmPAP values tended to have higher BMI values
(mean 19.5 vs. 18.6, p b 0.001) and end-match lung allocation
scores (mean 46.2 vs. 43.9, p b 0.001). Ischemic times were also
significantly different between the two cohorts (p = 0.047); those
with missing mPAP values tended to have higher ischemic times
(42% with ischemic times greater than 6 h as compared to 35%
among the non-missing cohort). Fig. 2 illustrates the Kaplan–
Meier estimates of survival for the missing and non-missing
mPAP values. Although not statistically significant, it appears
those with non-missing mPAP values may have a slight survival
advantage (log-rank p-value = 0.172): the median survival for
those with missing mPAP is 61.4 months as compared to
77.9 months for those with non-missing mPAP values. Estimated
hazard ratios and 95% CI from the multiple imputation procedure
are outlined in Table 4. The results and overall conclusions from
both the complete case analysis as well as the multiple imputation
procedure are similar, although the multiple imputation estimates
of the hazard ratios are closer to one.Table 3
Demographics by mean mPAP (mean pulmonary artery pressure) mm Hg.
Model N Comparison
Minimally adjusted a 831 Mean mPAP ≥ 25 vs. b25
Multivariable b 778 Mean mPAP ≥ 25 vs. b25
a Minimally adjusted model includes year of transplant and has the baseline haza
b Multivariable model includes year of transplant, induction (yes/no), age of recipien
gender, and steroid use, and has the baseline hazard stratified by region.4. Discussion
In this study, we sought to better define the prevalence of PH
in CF patients undergoing LTx and to assess the relationship
between PH and overall survival. Due to the majority of the
current published work being single-center experiences, there is a
wide variability in the prevalence of PH in the CF population.
Therefore, we used a large registry database involving multiple
institutions to described PH as a very common co-morbidity in CF
patients awaiting LTx. Moreover, we found no strong evidence to
suggest PH affects CF patients overall survival after LTx.
4.1. Survival
Our study results are similar to the findings in two other
previous studies [4,5] that PH is mild in CF patients undergoing
LTx. Furthermore, there was no statistically significant impact
on survival. Using RHC-acquired data obtained at a single
center over a 10-year period, Belle-van Meerkerk et al. [4]
reported 26% (24/93) if CF patients met the criteria for PH. TheEstimated HR 95% CI p-Value
0.830 (0.645, 1.067) 0.146
0.862 (0.653, 1.138) 0.293
rd stratified by region.
t, end-match lung allocation score, diabetes, recipient body mass index, recipient
Fig. 2. Kaplan–Meier estimates of post-lung transplant survival in recipients
with missing and non-missing mPAP data (log-rank p-value = 0.172).
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63% (36/57) of CF patients having PH with a 5-year mortality
that was not statistically significant between patients with or
without PH, but there was a trend for higher mortality in the PH
group, with a clear decline in survival if the left ventricular
ejection fraction was b55%.
In contrast to a tendency of worsening survival in the PH
group, we found a slight survival benefit of having PH in CF
patients after LTx, albeit not reaching statistical significance. This
difference cannot be explained based on the severity of PH since
the cohorts in both the Tonelli et al. [5] study and the current study
would be categorized as mild PH. We speculate that this trend in
improved survival seen in our cohort could be due to the benefit of
treating two potentiating co-morbidities, i.e. CF and PH, with
LTx. However, we cannot exclude that CF patients with more
severe PH are dying before undergoing LTx since we did not
analyze pre-transplant data. We cannot determine the exact
mechanism for our findings with a retrospective study, but our
findings clearly support the need for further research in this area.
4.2. Gender differences
Comparing PH vs. the non-PH groups in the current study,
the only non-pulmonary function variable that we found to be
significantly different between the groups was gender, i.e. CF
males were more frequently affected with PH. Tonelli et al. [5]
in their cohort of 57 CF patients (24 males) found no difference
in gender between the PH and non-PH groups. The currentTable 4
Model results with multiple imputation vs. complete case.
Model Imputed Estimated HR:
mPAP ≥ 25
vs. b25
95% CI p-Value
Minimally
adjusted
None 0.83 (0.65, 1.07) 0.146
mPAP values 0.90 (0.69, 1.18) 0.450
PAH 0.84 (0.65, 1.09) 0.197
Multivariable None 0.86 (0.65, 1.14) 0.293
mPAP values 0.92 (0.68, 1.23) 0.551
PAH 0.87 (0.65, 1.16) 0.333medical literature is somewhat conflicted with regard to gender
and advancing lung disease in CF. Using the United States
Cystic Fibrosis Foundation Patient Registry, female adolescents
were found to have more pulmonary exacerbations after
puberty; [23] whereas data from the Epidemiologic Study of
Cystic Fibrosis identified that male gender was a risk factor for
substantial pulmonary decline when comparing annual rates of
decline in FEV1 during adolescence and young adulthood when
stratified by best FEV1 at 18 years of age [24]. Differences in
gender regarding progression of lung disease and its related
complications in CF definitely need further investigation.
4.3. Prevalence
Despite the fact that the complication rate of RHC at
experienced centers is low [25], it is an invasive procedure with
limited use in select patient populations and often is not
performed until the time for LTx, including CF. Therefore,
echocardiography is often used as a surrogate for diagnostic
and research as in CF with resultant wide variations in
prevalence rates of PH [10–19]. The limitations of echocar-
diography are not innate to CF but include lung disease in
general [3,26–28]. Tonelli et al. [5] reported a higher
prevalence of PH in CF than previously reported at 63% (36/
57). We observed a similar prevalence rate but in a multi-
institutional cohort of CF patients. Furthermore, PH in the CF
population based on data currently reported to the UNOS/
OPTN STAR database would be considered mild with a mean
mPAP of 31.4 mm Hg in the PH group in the current study.
As expected, the PH group had a lower FEV1% of predicted
and a higher concentration of supplemental oxygen require-
ment at rest. All of these factors resulted in a higher mean lung
allocation score for the CF patients in the PH group.
4.4. Other risk factors
Older studies demonstrate that PH is a risk factor associated
with higher risk of death in patients with CF [29,30]. A more
recent retrospective data including four academic medical
centers found a trend towards right ventricular dysfunction and
not PH being associated with higher risk of death [7]. The
UNOS/OPTN STAR database is limited in the fact that the only
cardiac variable available was cardiac output, which showed no
significant difference between the PH and non-PH groups.
However, a specific strength of our study is the population of
patients being from a multi-institutional, large registry database
of transplant patients, reducing potential biases observed in
single-institution observational studies.
4.5. Limitations
Our study has several limitations, including the retrospective
collection of data and the lack of granularity of the database.
The sample size is small relative to the population of lung
transplants with a small proportion of patients who died.
Therefore, it is difficult to accurately estimate the survival
function within groups, thus limiting the power to detect
422 D. Hayes Jr. et al. / Journal of Cystic Fibrosis 13 (2014) 416–423differences in survival between groups. Additionally, the study
is challenged by incomplete data; we attempted to address the
missing mPAP data using multiple imputation. Some of the
mPAP values used to determine PH were from listing with
variable times on the waitlist. Also, when both the listing and
transplant values were present they were often identical which
raises question regarding whether or not they were actually
separate values or one value that was either back entered or
carried forward.
5. Conclusions
Despite being very common in CF, PH did not appear to
adversely impact outcomes after LTx; therefore, we conclude
that there is no strong evidence that PH alters the risk for
death in the CF population after LTx. However, we identified
areas that need further research regarding PH in the CF
population.
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